AzTrials
AzTrials

Frailty SyndromeFEMURNCT04764617

Functioning of Elder Muscle; Understanding Recovery

An observational study of Frailty Syndrome, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

As people get older, the amount of skeletal muscle in the body can decrease. When the amount of this muscle in the body gets very low, there is an increased risk of falling, and not only is recovery to any injury slower, but more complications can be experienced following surgery, and patients may end up being more… Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Frailty Syndrome
How many people
80 participants
Where
1 siteUnited Kingdom
Study dates
4 Jan 2021to 31 Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Individuals >65 years who have been admitted to Queens Medical Centre, Nottingham, UK for surgical repair of a hip fracture sustained following a low impact fall.

Who may be able to join

  • Clinical Frailty Score (assessed as part of standard care) ≥ 4
  • Fractured hip, sustained following a fall, that requires surgery
  • Good understanding of spoken and written English language
  • Able to give informed consent, or availability of a legally acceptable surrogate to provide consent

Who cannot join

  • Those who fell and sustained their hip fracture greater than 12 hours prior to hospitalisation.
  • Those who have fallen and sustained a hip fracture whilst an in-patient in hospital
  • Those who sustained the hip fracture as a result of high impact trauma (e.g. road traffic accident)
  • Surgery carried out later than 96 hrs after fall
  • Chronic neurological, inflammatory or musculoskeletal disorders which result in muscle wasting, e.g. Multiple sclerosis, muscular dystrophy, rheumatoid arthritis
  • Any co-morbidity which precludes hip surgery
  • Those with a compromised swallowing reflex which would prevent the participant from taking fluids orally, will be excluded.
  • Those taking diabetes medication

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Queens Medical Centre; Department of Orthopaedics

    Nottingham, NG72UH

Other trials in United Kingdom

About this study

Official title: Muscle Phenotyping in Frail Older Patients Having Hip Surgery Following Fracture

As people get older, the amount of skeletal muscle in the body can decrease. When the amount of this muscle in the body gets very low, there is an increased risk of falling, and not only is recovery to any injury slower, but more complications can be experienced following surgery, and patients may end up being more dependent on the help of others for meeting daily activities. However, it is not clear whether it is simply the amount of muscle that is in the body that is important for health, or whether it is the ability of muscle to function properly which is important.

This research study is looking at the way muscles of frail older people function; not just how strong they are, but the amount of fats and protein that there are in muscle cells, and how the genes in the muscles are being expressed (genes being a collection of chemical information that carry the instructions for making the proteins a cell will need to function).

We will also investigate whether recovery from hip fracture is impacted by the amount of muscle that there is in the body, and/or the functioning of this muscle.

Read the detailed description

Sarcopenia is the age-associated loss of skeletal muscle mass, muscle quality and strength, and is a contributive factor to frailty in older individuals. Meta-analyses suggest that individuals with sarcopenia appear to be at greater risk of hospitalisation (all cause), falls and fracture, with hip fracture following a fall being both a serious consequence of sarcopenia, as well as a risk factor for frailty syndrome. The short and longer term outcomes for patients who have a hip fracture following a fall are poor (post-operative complications, increased length of hospital stay, and increased mortality risk, institutionalisation and dependency, respectively), and these are understood to be largely due to the underlying vulnerability (frailty) of the people who sustain hip fractures, with poor recovery being compounded by the reduced muscle strength and low muscle mass common in those who are frail.

As a consequence of research on the physiology of ageing muscles and sarcopenia, increasingly there is the possibility that novel agents (such as anabolic agents) could help to alleviate the frailty state in these patients and hence improve shorter and longer term outcomes. However, before novel interventions can be applied to patients with frailty and sarcopenia, such as those sustaining a hip fracture following a fall, an understanding of how the muscles of these patients are functioning at the cellular level, both in the injured and uninjured state is needed; which metabolic pathways are active and which are inactive, those which are enhanced and those which are impaired, so that treatments that are appropriate for the specific metabolic state of these patients can be selected. In recent years there have been advances in the understanding of the cellular physiology of the muscles of older people. However, few of the research studies carried out to date have analysed muscle collected from individuals who are as frail as the patients who present with hip fractures, or probed the metabolic changes which occur in the muscle following injury in this cohort. Findings from cross-sectional investigations on the healthy older person and prospective studies which try and mimic the muscle wasting seen in sarcopenia (using immobilisation or bed rest protocols) could prove useful in this endeavour. However, it is possible that results from these studies may not be generalizable to those who are frail (who may have other clinical problems and take multiple medications) and it is important that deep phenotyping of muscle from these patients is undertaken to address this knowledge gap.

Across the whole study, including a cohort subset, a range of people with frailty, including those with cognitive impairment will be studied. Those with dementia or severe cognitive impairment tend to be those who are most frail and represent a high proportion of patients admitted with a hip fracture. If such patients are excluded, there is a risk of only observing muscle metabolic and histological changes seen in milder levels of frailty, which may not provide a comprehensive picture of sarcopenia. This is a frequent criticism and limitation of previous studies carried out in this field.

Participants will be older individuals admitted to Nottingham University Hospital (UK) with a fractured hip sustained following a fall. In all participants, a muscle sample will be taken from their injured leg during the surgical repair to their hip, with the option for a muscle biopsy to be taken, whilst in theatre, from their uninjured leg using the Bergstrom technique. These samples will be analysed for intramyocellular lipid content and messenger ribonucleic acid (mRNA) expression of 384 gene targets spanning a number of cellular functions. In the week following surgery, measurements of thigh muscle thickness (Ultrasound imaging) and hand grip strength will be made, and an optional assessment of whole body muscle mass using the D3-creatine method will be offered. After discharge from hospital, patient-related outcomes measures will be obtained from medical notes and Three months after surgery, a set of questionnaires will be sent to the participant or their carer to complete. These will assess current mobility, dependency and wellbeing.

Medical subject headings
Frailty

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Skeletal Muscle messenger ribonucleic acid (mRNA) expression (injured leg)

    mRNA expression of 384 gene targets spanning a number of cellular functions, in a vastus lateralis muscle biopsy taken from the injured leg

    Measured: On recruitment

Secondary outcomes (23)
  1. Skeletal Muscle mRNA expression (un-injured leg)

    mRNA expression of 384 gene targets spanning a number of cellular functions, in a vastus lateralis muscle biopsy taken from the uninjured leg

    Measured: On recruitment

  2. Intramyocellular lipid density (injured leg)

    Intra-myocellular lipid density in a vastus lateralis muscle biopsy taken from the injured leg

    Measured: On recruitment

  3. Intramyocellular lipid density (uninjured leg)

    Intra-myocellular lipid density in a vastus lateralis muscle biopsy taken from the uninjured leg

    Measured: On recruitment

  4. Body weight

    body mass (kg)

    Measured: on recruitment

  5. Grip Strength

    Hand grip strength measured on dominant arm - highest of 3 attempts

    Measured: up to 3 days post surgery

  6. Groningen Frailty Indicator (GFI) questionnaire

    Groningen Frailty Indicator Score: minimum value (no frailty) indicated by a score of 0, increasing to a maximum value of 15 (completely disabled). Frailty is indicated by a score ≥4, with lower scores indicating better outcomes

    Measured: on recruitment

  7. Groningen Frailty Indicator (GFI) questionnaire

    Groningen Frailty Indicator Score: minimum value (no frailty) indicated by a score of 0, increasing to a maximum value of 15 (completely disabled). Frailty is indicated by a score ≥4, with lower scores indicating better outcomes

    Measured: 1 week post operative

  8. Groningen Frailty Indicator (GFI) questionnaire

    Groningen Frailty Indicator Score: minimum value (no frailty) indicated by a score of 0, increasing to a maximum value of 15 (completely disabled). Frailty is indicated by a score ≥4, with lower scores indicating better outcomes

    Measured: 90 days post operative

  9. Barthel Index for Activities of Daily Living (BADL) questionnaire

    Barthel Index for Activities of Daily Living score: minimum value (totally independent) indicated by a score of 0, increasing to a maximum value of 60 (totally dependent). Lower scores indicate better outcomes

    Measured: on recruitment

  10. Barthel Index for Activities of Daily Living (BADL) questionnaire

    Barthel Index for Activities of Daily Living score: minimum value (totally independent) indicated by a score of 0, increasing to a maximum value of 60 (totally dependent). Lower scores indicate better outcomes

    Measured: 1 week post operative

  11. Barthel Index for Activities of Daily Living (BADL) questionnaire

    Barthel Index for Activities of Daily Living score: minimum value (totally independent) indicated by a score of 0, increasing to a maximum value of 60 (totally dependent). Lower scores indicate better outcomes

    Measured: 90 days post operative

  12. Rivermead Mobility Index (RMI) Questionnaire

    Rivermead Mobility Index score: minimum value (immobile) indicated by a score of 0, increasing to a maximum value of 15. Higher scores indicate better mobility and better outcomes

    Measured: on recruitment

  13. Rivermead Mobility Index (RMI) Questionnaire

    Rivermead Mobility Index score: minimum value (immobile) indicated by a score of 0, increasing to a maximum value of 15. Higher scores indicate better mobility and better outcomes

    Measured: 1 week post operative

  14. Rivermead Mobility Index (RMI) Questionnaire

    Rivermead Mobility Index score: minimum value (immobile) indicated by a score of 0, increasing to a maximum value of 15. Higher scores indicate better mobility and better outcomes

    Measured: 90 days post operative

  15. EuroQoL health-related quality of life questionnaire (EQ-5D)

    EuroQoL health-related quality of life questionnaire score: across each of 5 domains, a minimum value of 1 indicates no problems, increasing to a maximum value of 5 indicating an inability to do a task, or an extreme experience of a sensation. Lower scores indicate better outcomes

    Measured: 1 week post operative

  16. EuroQoL health-related quality of life questionnaire (EQ-5D)

    EuroQoL health-related quality of life questionnaire score: across each of 5 domains, a minimum value of 1 indicates no problems, increasing to a maximum value of 5 indicating an inability to do a task, or an extreme experience of a sensation. Lower scores indicate better outcomes

    Measured: 90 days post operative

  17. Vastus lateralis muscle thickness - injured leg

    Vastus lateralis muscle thickness measured at the midpoint using ultrasonography

    Measured: 3 days post operative

  18. Vastus lateralis muscle thickness - uninjured leg

    Vastus lateralis muscle thickness measured at the midpoint using ultrasonography

    Measured: 3 days post operative

  19. Whole body muscle mass

    whole body muscle mass assessed using the D3-Creatine method

    Measured: 3 days post operative

  20. Clinical outcomes; surgical complications

    occurrence of surgical complications audited from patient notes prior to discharge

    Measured: from date of surgery to date of discharge from hospital; up to 90-days after hip surgery

  21. Clinical outcomes; adverse events during period of hospitalisation

    occurrence of adverse events collected throughout period of hospitalisation

    Measured: from date of recruitment to date of discharge from hospital; up to 90-days post operative.

  22. Clinical outcomes; length of stay

    Length of hospitalisation period audited from patient notes prior to discharge

    Measured: at discharge from hospital; up to 90 days post hip surgery

  23. Clinical outcomes; discharge location

    discharge location audited from patient notes prior to discharge

    Measured: at discharge from hospital; up to 90 days post hip surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2021
  2. Study start4 Jan 2021
  3. Primary completion31 Dec 2024
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04764617
Sponsor's protocol ID
20/LO/0841
Acronym
FEMUR
Status last verified
Aug 2025
First submitted
8 Feb 2021
Last updated
1 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: gene expression data will be made available in a open access data depository after publication.

Publications

  • Valdes AM, Ikram A, Taylor LA, Zheng A, Kouraki A, Kelly A, Ashraf W, Vijay A, Miller S, Nightingale J, Selby NM, Ollivere BJ. Preoperative inflammatory biomarkers reveal renal involvement in postsurgical mortality in hip fracture patients: an exploratory study. Front Immunol. 2024 Jun 10;15:1372079. doi: 10.3389/fimmu.2024.1372079. eCollection 2024.

    PubMed 38919625

Questions about this trial

What is this clinical trial studying?

An observational study of Frailty Syndrome, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Skeletal Muscle messenger ribonucleic acid (mRNA) expression (injured leg) (time frame: On recruitment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04764617, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in